There are 30 papers on CA19-9 in aging research: 1 trial and 24 observational studies in people, 4 reviews.
30 papers study it13 more mention it8 findings
9 new papers in 30 daysSee all 43 papers on CA19-9
“with CA19-9 achieving the highest overall performance of 0.94 (95% CI: 0.86-1.00).”
- Human trial1
- Humans24
Effects
1PDAC risk factor count
no changein humans1
1 study
PDAC risk factor count
no changein humans1
CA19-9 was not clearly linked with PDAC risk factor count in humans.
“No difference between normal and abnormal results were observed for CA19-9.”
Humansn = 265
Preprints.orgPreprint
Upstream
1Skeletal muscle and adipose tissue loss
no changein humans1
1 study
Skeletal muscle and adipose tissue loss
no changein humans1
Skeletal muscle and adipose tissue loss was not clearly linked with CA19-9 in pancreatic cancer cases.
“are not correlated with at-diagnosis circulating levels of CA19-9”
Humansin pancreatic cancer casesblood
Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer
Nature communications
Associations
6Concomitant pancreatic ductal adenocarcinoma
upin humans1
1 study
Concomitant pancreatic ductal adenocarcinoma
upin humans1
CA19-9 predicts concomitant pancreatic ductal adenocarcinoma in humans.
“CA19-9 elevation and new or worsening diabetes predicted cPDAC.”
HumansPatients with branch-duct intraductal papillary mucinous neoplasm without baseline worrisome features or high-risk stigmataUp to 5.17 years
Annals of surgery
PDAC diagnosis
upin humans1
1 study
PDAC diagnosis
upin humans1
CA19-9 predicts PDAC diagnosis in humans (patients with benign pancreatic diseases) (AUC 0.96 vs. 0.87, P = 0.003).
“significant differences at 0-3 months (0.96 vs. 0.87, P = 0.003)”
Humanspatients with benign pancreatic diseasesserum0-3 months before diagnosis
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Early detection of PDAC
upin humans1
1 study
Early detection of PDAC
upin humans1
CA19-9 predicts early detection of PDAC in humans (patients with benign pancreatic diseases) (AUC 0.69 vs. 0.56, P = 0.004).
“From 12 to 18 months before diagnosis, the logistic regression model demonstrated higher AUC values than the conventional cutoff of 37 U/mL”
Humanspatients with benign pancreatic diseasesserum12-18 months before diagnosis
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Pancreatic cancer
upin humans1
1 study
Pancreatic cancer
upin humans1
CA19-9 predicts pancreatic cancer in humans (new-onset diabetes; PDAC versus non-cancer controls) (AUC 0.94 (95% CI 0.86–1.00); sensitivity 83.3% at 97.2% specificity).
“with CA19-9 achieving the highest overall performance of 0.94 (95% CI: 0.86-1.00).”
Humansnew-onset diabetes; PDAC versus non-cancer controlsplasma3 yearsn = 2,121
medRxiv : the preprint server for health sciencesPreprint
Colorectal polyp
mixedin humans1
1 study
Colorectal polyp
mixedin humans1
CA19-9 predicts colorectal polyp in humans (Feature importance analysis) (Top predictive factor).
“Feature importance analysis revealed CA19-9 as the top predictive factor.”
HumansFeature importance analysisn = 946
BMC gastroenterology
Pancreatic ductal adenocarcinoma
upin humans1
1 study
Pancreatic ductal adenocarcinoma
upin humans1
CA19-9 predicts pancreatic ductal adenocarcinoma in humans (PDAC vs controls) (AUC 91.7 [95% CI, 87.8-95.6]).
“the AUC for serum CA19-9 alone was 91.7 [95% confidence interval (CI), 87.8-95.6]”
HumansPDAC vs controls
Blood test panel better distinguished pancreatic cancer cases
Clinical cancer research : an official journal of the American Association for Cancer Research